CA2933601A1 - Angiotensin ii alone or in combination for the treatment of hypotension - Google Patents

Angiotensin ii alone or in combination for the treatment of hypotension Download PDF

Info

Publication number
CA2933601A1
CA2933601A1 CA2933601A CA2933601A CA2933601A1 CA 2933601 A1 CA2933601 A1 CA 2933601A1 CA 2933601 A CA2933601 A CA 2933601A CA 2933601 A CA2933601 A CA 2933601A CA 2933601 A1 CA2933601 A1 CA 2933601A1
Authority
CA
Canada
Prior art keywords
dose
angiotensin
catecholamine
norepinephrine
mcg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2933601A
Other languages
English (en)
French (fr)
Inventor
Lakhmir Chawla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
George Washington University
Original Assignee
George Washington University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53367119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2933601(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by George Washington University filed Critical George Washington University
Publication of CA2933601A1 publication Critical patent/CA2933601A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2933601A 2013-12-18 2014-12-18 Angiotensin ii alone or in combination for the treatment of hypotension Pending CA2933601A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361917576P 2013-12-18 2013-12-18
US61/917,576 2013-12-18
US201461955706P 2014-03-19 2014-03-19
US61/955,706 2014-03-19
PCT/US2014/071186 WO2015095535A1 (en) 2013-12-18 2014-12-18 Angiotensin ii alone or in combination for the treatment of hypotension

Publications (1)

Publication Number Publication Date
CA2933601A1 true CA2933601A1 (en) 2015-06-25

Family

ID=53367119

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2933601A Pending CA2933601A1 (en) 2013-12-18 2014-12-18 Angiotensin ii alone or in combination for the treatment of hypotension

Country Status (25)

Country Link
US (7) US9220745B2 (https=)
EP (2) EP3607962B1 (https=)
JP (4) JP6824739B2 (https=)
KR (4) KR20220028125A (https=)
CN (4) CN119700926A (https=)
AU (3) AU2014364528C1 (https=)
BR (1) BR112016013961A2 (https=)
CA (1) CA2933601A1 (https=)
CY (1) CY1122604T1 (https=)
DK (2) DK3607962T3 (https=)
EA (1) EA037823B1 (https=)
ES (2) ES3055611T3 (https=)
FI (1) FI3607962T3 (https=)
HR (2) HRP20200009T1 (https=)
HU (1) HUE047062T2 (https=)
IL (1) IL246162B (https=)
LT (2) LT2986308T (https=)
MX (2) MX380968B (https=)
NZ (1) NZ721089A (https=)
PL (2) PL2986308T3 (https=)
PT (2) PT3607962T (https=)
RS (2) RS67626B1 (https=)
SI (2) SI3607962T1 (https=)
SM (2) SMT202500427T1 (https=)
WO (1) WO2015095535A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9572856B2 (en) 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
PL2986308T3 (pl) 2013-12-18 2020-05-18 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation Angiotensyna ii w połączeniu do leczenia niedociśnienia
WO2016007589A1 (en) * 2014-07-08 2016-01-14 La Jolla Pharmaceutical Company Methods for treating hypotension
WO2016153558A1 (en) 2015-03-20 2016-09-29 Atkinson Arthur J Use of angiotensin ii (aii) receptor agonists to prevent or reduce hemodialysis-associated skeletal muscle cramps
PL3400000T3 (pl) * 2016-01-07 2024-04-22 La Jolla Pharma, Llc Sposoby podawania angiotensyny ii
EP3400001A1 (en) * 2016-01-07 2018-11-14 La Jolla Pharmaceutical Company Methods of administering vasopressors
WO2018191678A1 (en) * 2017-04-14 2018-10-18 La Jolla Pharmaceutical Company Methods for administering angiotensin ii
WO2019118874A1 (en) * 2017-12-15 2019-06-20 La Jolla Pharma, Llc Angiotensin compositions and methods related thereto
WO2023244552A1 (en) * 2022-06-15 2023-12-21 Virginia Commonwealth University Methods for fluid resuscitation of an organ donor
EP4633658A1 (en) * 2022-12-12 2025-10-22 Proletariat Therapeutics, Inc. Methods of treating cardiac injury

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU181008B (en) 1980-01-18 1983-05-30 Richter Gedeon Vegyeszet Process for producing angiotenzin-ii analogues of antagonistic activity containing sarcosyl-group at the 1-positon,and an alpha-hydroxy-carboxylic acid at the 8-position
US5216025A (en) * 1989-09-13 1993-06-01 Board Of Regents, The University Of Texas System Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
US6592865B2 (en) 2001-06-04 2003-07-15 Human Genome Sciences, Inc. Methods and compositions for modulating ACE-2 activity
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
NO20034952D0 (no) 2003-11-06 2003-11-06 Amersham Health As Farmasöytiske forbindelser
WO2005044313A2 (en) 2003-11-06 2005-05-19 Amersham Health As Conjugates of angiotensin ii and an imaging moiety
FR2880807B1 (fr) * 2005-01-19 2007-04-13 Aguettant Sa Lab Composition pharmaceutique injectable
US20070072817A1 (en) 2005-09-29 2007-03-29 Fibrogen, Inc. Methods for reducing blood pressure
JP2009521513A (ja) 2005-12-30 2009-06-04 ハワード・フロレイ・インスティチュート・オブ・エクスペリメンタル・フィスィオロジー・アンド・メディシン 治療の方法
CA2655144A1 (en) 2006-06-15 2007-12-21 Gilead Colorado, Inc. Antihypertensive therapy method
WO2008130217A1 (en) * 2006-08-08 2008-10-30 Applied Nanosystems B.V. Cyclic angiotensin analogs
WO2008059062A1 (en) 2006-11-17 2008-05-22 Da Volterra Colonic delivery using zn/pectin beads with a eudragit coating.
WO2009009907A1 (en) * 2007-07-18 2009-01-22 The University Of British Columbia Use of vasopressin-receptor agonists for the treatment of septic shock
EP2161030A1 (en) * 2008-09-09 2010-03-10 Rijksuniversiteit te Groningen Oxytocin formulations and uses thereof
RU2011126338A (ru) 2008-11-28 2013-01-10 Эбботт Лэборетриз Стабильные композиции антител и способы их стабилизации
US9572856B2 (en) 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
FR2959414B1 (fr) * 2010-04-30 2016-01-08 Luc Quintin Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire
KR20130026504A (ko) 2010-07-14 2013-03-13 큠버랜드 에멀징 테크놀로지스 아이앤씨 트롬복산-a2 수용체 길항제를 이용한 간신증후군 및 간성뇌증의 치료방법
EP2988770A4 (en) 2013-04-26 2016-12-14 La Jolla Pharma Co COMPOSITIONS AND METHOD FOR TREATING KIDNEY FAILURES
PL2986308T3 (pl) 2013-12-18 2020-05-18 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation Angiotensyna ii w połączeniu do leczenia niedociśnienia
US20150286797A1 (en) 2014-04-02 2015-10-08 David R. Ratto System and method for administering medication
WO2016007589A1 (en) 2014-07-08 2016-01-14 La Jolla Pharmaceutical Company Methods for treating hypotension
EP3400001A1 (en) 2016-01-07 2018-11-14 La Jolla Pharmaceutical Company Methods of administering vasopressors
PL3400000T3 (pl) 2016-01-07 2024-04-22 La Jolla Pharma, Llc Sposoby podawania angiotensyny ii
WO2018191678A1 (en) 2017-04-14 2018-10-18 La Jolla Pharmaceutical Company Methods for administering angiotensin ii
WO2019118874A1 (en) 2017-12-15 2019-06-20 La Jolla Pharma, Llc Angiotensin compositions and methods related thereto

Also Published As

Publication number Publication date
JP6824739B2 (ja) 2021-02-03
CN112546197A (zh) 2021-03-26
RS59804B1 (sr) 2020-02-28
US20150164980A1 (en) 2015-06-18
CN106061493A (zh) 2016-10-26
EP2986308A1 (en) 2016-02-24
US20180193407A1 (en) 2018-07-12
PL3607962T3 (pl) 2026-03-09
PT2986308T (pt) 2020-01-21
AU2014364528A9 (en) 2016-07-28
US20160129072A1 (en) 2016-05-12
US10493124B2 (en) 2019-12-03
ES3055611T3 (en) 2026-02-13
EP3607962A1 (en) 2020-02-12
WO2015095535A9 (en) 2016-07-14
SMT202000018T1 (it) 2020-03-13
US20190328827A1 (en) 2019-10-31
LT2986308T (lt) 2020-03-25
CN111920939A (zh) 2020-11-13
WO2015095535A1 (en) 2015-06-25
KR20160117437A (ko) 2016-10-10
US11096983B2 (en) 2021-08-24
SMT202500427T1 (it) 2026-01-12
JP2025114753A (ja) 2025-08-05
AU2020277230A1 (en) 2020-12-24
US9220745B2 (en) 2015-12-29
KR102399383B1 (ko) 2022-05-19
AU2014364528A1 (en) 2016-06-30
EA037823B1 (ru) 2021-05-25
FI3607962T3 (fi) 2025-11-24
SI3607962T1 (sl) 2026-02-27
IL246162A0 (en) 2016-07-31
ES2771749T3 (es) 2020-07-07
MX2020011190A (es) 2020-11-13
NZ721089A (en) 2022-10-28
KR20220028125A (ko) 2022-03-08
EA201691258A1 (ru) 2016-11-30
CN119700926A (zh) 2025-03-28
HRP20251406T1 (hr) 2026-02-27
AU2014364528B2 (en) 2020-08-27
IL246162B (en) 2020-03-31
JP2022137224A (ja) 2022-09-21
DK2986308T3 (en) 2020-01-27
RS67626B1 (sr) 2026-02-27
KR20240154702A (ko) 2024-10-25
MX2016008108A (es) 2017-03-09
US11559559B2 (en) 2023-01-24
AU2024219851A1 (en) 2024-10-10
JP2017501154A (ja) 2017-01-12
US10765722B2 (en) 2020-09-08
US20190070250A1 (en) 2019-03-07
JP2019214610A (ja) 2019-12-19
BR112016013961A2 (pt) 2017-10-10
HRP20200009T1 (hr) 2020-03-20
LT3607962T (lt) 2026-01-12
HUE047062T2 (hu) 2020-04-28
CY1122604T1 (el) 2021-03-12
AU2014364528C1 (en) 2021-01-07
PL2986308T3 (pl) 2020-05-18
EP3607962B1 (en) 2025-08-13
EP2986308A4 (en) 2017-01-11
JP7175506B2 (ja) 2022-11-21
US10028995B2 (en) 2018-07-24
DK3607962T3 (da) 2025-11-17
SI2986308T1 (sl) 2020-03-31
PT3607962T (pt) 2025-11-18
US20220047669A1 (en) 2022-02-17
KR20230051721A (ko) 2023-04-18
EP2986308B1 (en) 2019-10-16
US20230226141A1 (en) 2023-07-20
MX380968B (es) 2025-03-12

Similar Documents

Publication Publication Date Title
US11559559B2 (en) Angiotensin II alone or in combination for the treatment of hypotension
WO2018191678A1 (en) Methods for administering angiotensin ii
HK40050536A (en) Angiotensin ii alone or in combination for the treatment of hypotension
HK40039808A (en) Angiotensin ii alone or in combination for the treatment of hypotension
HK1229245A1 (en) Angiotensin ii alone or in combination for the treatment of hypotension

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191127

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241213

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241213

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250416

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250815

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250819

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251022

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251022

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251226

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251226

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260225